This annex provides the list of consultations undertaken in support of this evaluation. Consultee Table B.1: Global consultee list Stakeholder Organisation Name Position Unitaid Unitaid Secretariat Robert Matiru Operations Director Smiljka de Lussigny Programme Manager Lorenzo Witherspoon Procurement Officer Carmen HIV Strategy Manager Philippe Duneton Deputy Executive Director Dopas Finance Manager Vincent Bretin Team Lead, Results Gauri Khanna M&E Manager Project Grantee MSF Stephan Grosserueschkamp Manager (from January 2017 to October 2017) Mikhael de Souza Grant Manager (2013-2016) Camille Baillat Finance Manager (from October 2016) Teri Roberts Diagnostic Advisor MSF-Belgium Marc Biot Program Manager MSF-Switzerland Javier Goiri Deputy Program Manager MSF-Southern African Medical Unit (SAMU) Tom Ellman Director MSF-Supply Eric Field Procurement Expert Global Partners WHO Lara Vojnov HIV Diagnostics Advisor Meg Doherty WHO Coordinator, HIV Treatment and Care USAID Dianna Edgil Senior Laboratory Adviser CHAI Trevor Peter Head of CHAI Laboratory Team Zach Katz Former Head of CHAI Laboratory Team CDC Debi Boeras Former Head of the VL/EID Section of The International Laboratory Branch
2013-16 C.1: Unitaid 2013-2016 Strategic Objectives and grant relevance Strategic objective Market shortcoming sought to be addressed through the project Description of project aims and alignment with Strategic Objective/ market shortcoming 1: Increase access to simple, diagnostics for HIV/AIDS, TB, and malaria Affordability: Traditional HIV diagnostics performed in sophisticated laboratory settings are unaffordable for settings. Quality Absence of information on quality of newer POC diagnostics. Acceptability/ Adaptability: Traditional, laboratory-based products are ill-adapted for low-resource settings because they are complicated to use and maintain, and require sophisticated infrastructure and skilled technicians. Newer POC diagnostics currently on the market allow for more decentralized testing but many are still too complicated for use in remote settings by unskilled workers. Delivery: Slow and insufficient uptake of both traditional laboratory-based and newer POC diagnostics. Within the project aims, operational research was to be conducted on feasibility, acceptability, sustainability, and affordability of POC testing and laboratory-based tools to determine optimal implementation approaches across a range of settings. In addition, informal assessments on the quality of the products were to be conducted. As such, the focus of the project was on acceptability/ adaptability and delivery, although it also touched upon affordability and quality. 2: Increase access to affordable, adapted paediatric medicines to HIV/AIDS, tuberculosis, and malaria Delivery: Few children are initiated on HIV treatment to 18 months of age as recommended. Project indirectly contributed towards this objective by aiming to improve access to EID. 3: Increase access to emerging medicines and/or regimens as well as new formulations, dosage forms, or strengths of existing medicines that will improve treatment of HIV/AIDS and Affordability: High prices of existing products Delivery: Low uptake of second-line regimens; almost no uptake of regimens in LICs. Project indirectly contributed to this objective by increasing the understanding of the need for second and third line treatment, and feasibility of testing and switching in LICs. The project aimed to provide lessons learned and best practices to WHO for incorporation into Treatment 2.0 guidance.
settings, with some evidence of declining service provision post MSF hand-over. The main contribution of the project however has been its demonstration of proof of concept which has helped set the stage for longer term scalability of routine VL monitoring. 5.2 Scaling-up coverage (Additional number of people who benefit from a better health product or approach)